Gold bullion on american dollar banknotes close up

C4X Discovery Holdings plc (LON:C4XD) will work with a renowned industry veteran who will create and lead its drug discovery network.

The mission of Robin Carr, who has worked with both GlaxoSmithKline and Astex, is to bring together small molecule drug discovery and development experts from across the globe.

The idea is to harness industry expertise to build on C4XD’s drug discovery capabilities and attract valuable relationships that have the potential to advance its goal of becoming the world’s most productive drug discovery company, the company said.

Carr and his team will act as ambassadors for C4XD within the biotech and pharmaceutical community, “building awareness of the company’s technologies, capabilities and business”.

Chief executive Clive Dix explained: “As part of our strategy to become the world’s most productive drug discovery company, we are continually enhancing both our network and expertise. 

“As international thought leaders, the advisory network’s deep industry expertise will enable us to accelerate progress of our portfolio and we are particularly proud that Robin will be chair.

“Under Robin’s guidance, we believe the advisory network will advance our vision and reputation within the industry.”

C4X’s stated aim is to become the world’s most productive drug discovery engine.

To achieve this goal it is using cutting-edge technologies and expertise to efficiently deliver small-molecule (pharmaceutical) medicines.

It has a unique software platform for determining the flexible 3D shapes of drug molecules from experimental data.

This enables the rapid design and discovery of novel and potent drugs for diseases with high unmet medical need across broad therapeutic areas.

Unlike many drug companies, it looks to find partners at the pre-clinical phase, allowing big pharma to fund expensive human trials.

It successfully out-licensed its programme for addictive disorders to Indivior, receiving an upfront £7.7mln (US$10mln) and milestones of £227mln (US$294mln).

It is working on potential treatments for Parkinson’s, Alzheimer’s and inflammatory bowel disorders and it has numerous collaboration deals.